PTGS2 and lung cancer: While clinical studies with COX-2 or IL-1B inhibitors have shown benefit in preventing the development of colon and lung cancers, respectively [25, 26], there is not yet evidence that these agents have an impact on established cancers, even when combined with ICB [27–29].